Evaluation of MPA and MPAG removal by continuous venovenous hemodiafiltration and continuous venovenous hemofiltration

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 100-102

  Cussonneau, Xavier ^a   Bolon Larger, Magali ^a,b   Prunet Spano, Céline ^a   Bastien, Olivier ^b   Boulieu, Roselyne ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b LOUIS PRADEL HOSPITAL   (France)

Author keywords

Continuous venovenous hemodiafiltration; Continuous venovenous hemofiltration; Drug removal; Mycophenolic acid

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SCREENING; FEMALE; HEART GRAFT; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BINDING; RENAL REPLACEMENT THERAPY; ULTRAFILTRATION;

EID: 38549170579     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181633667     Document Type: Article

References (17)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
2. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36:315-324.
3. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation. 2004;77:568-574.
4. Morgera S, Budde K, Lampe D, et al. Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis. Transpl Int. 1998;11:53-57.
5. Levraut J, Dellamonica J, Grimaud D. Adaptation des thérapeutiques médicamenteuses chez le patient en hémodiafiltration continue. In: Sfar, ed. Paris: Elsevier, Conférences d'Actualisation; 2002:607-619.
6. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
7. Zanker B, Schleibner S, Schneeberger H, et al. Mycophenolate mofetil in patients with acute renal failure: evidence of metabolite (MPAG) accumulation and removal by dialysis. Transpl Int. 1996;9:S308-S310.
8. Johnson HJ, Swan SK, Heim-Duthoy KL, et al. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther. 1998;63:512-518.
9. Isla A, Gascon AR, Maynar J, et al. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. Clin Ther. 2005;27:1444-1451.
10. Dirkes S, Hodge K. Continuous renal replacement therapy in the adult intensive care unit: history and current trends. Crit Care Nurse. 2007;27:61-81.
11. Bastien O, Boulieu R. Médicaments et èpuration extra rénale. In: 39 ème Congrés d'Anesthésie reanimation. Paris: Elsevier, Conférences d'actualisation; 1997:381-390.
12. Bickley S. Drug dosing during arterious hemofiltration. Clin Pharm. 1988;7:198-206.
13. Bolon M, Jeanpierre L, El Barkil M, et al. HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material. J Pharm Biomed Anal. 2004;36:649-651.
14. Cussonneau X, Bolon-Larger M, Boulieu R. Sorption of mycophenolic and its glucuronide (MPAG) to glass, polystyrene and polypropylene containers. Clin Chem. 2006;52:904-906.
15. Cussonneau X, Bolon-Larger M, Prunet-Spano C, et al. Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma. J Chromatogr B. 2007;852:674-678.
16. Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000;22:27-30.
17. Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.